Shares in Eli Lilly (NYSE:LLY) fell slightly this morning even though the pharmaceutical company beat analysts’ estimates with its fourth quarter and full-year financial results.
The Indianapolis-based company swung to a net loss in the fourth quarter, posting -$1.7 billion, or $1.85 per share, on sales of $6.2 billion for the 3 months ended Dec. 31, for sales growth of 7% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Eli Lilly beats the Street with Q4 earnings appeared first on MassDevice.